COMMUNIQUÉS West-GlobeNewswire

-
Triumph Steps Launches CLE-Eligible Mental Fitness Program for Lawyers
09/10/2025 -
Optime Care Terminates Distributor Agreement for Korlym® (mifepristone)
09/10/2025 -
Toro Neurovascular and Kaneka Announce Exclusive U.S. Distribution Partnership
09/10/2025 -
Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer
09/10/2025 -
Applications Now Open for Fall 2025 First Practice Fund Scholarship
09/10/2025 -
Alkeus Pharmaceuticals Announces Presentation of Gildeuretinol Data at the American Academy of Ophthalmology (AAO) 2025 Annual Meeting, October 18-21 in Orlando
09/10/2025 -
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
09/10/2025 -
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
09/10/2025 -
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial
09/10/2025 -
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
09/10/2025 -
Human Appeal's Pot of Gold Film to Air on EarthX Channel on October 18
09/10/2025 -
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
09/10/2025 -
U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade
09/10/2025 -
Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform
09/10/2025 -
Genvor Restores Trading Status and Expands Global Collaborative Research Network
09/10/2025 -
Dr. Mark Hyman joins ADvantage Therapeutics Advisory Board to further advance Klotho-Based Longevity Programs at Klothea Bio
09/10/2025 -
Tilray Brands Reports Strong First Quarter Fiscal 2026 Results, Highlighting Continued Growth with Record Q1 Net Revenue of $210 Million and Net Income
09/10/2025 -
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
09/10/2025 -
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
09/10/2025
Pages